SEARCH

SEARCH BY CITATION

References

  • Aidonidis I, Brachmann J, Rizos I, Toutouzas P, Kubler W (1994). Lidocaine converts inducible ventricular fibrillation into sustained ventricular tachycardia in conscious dogs with recent myocardial infarction. Cardiology 85: 378387.
  • Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF (2004). Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 95: 717725.
  • Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1S254.
  • Amitzur G, Shenkar N, Mueller M, Kraft P, Noviko I, Eldar M et al. (2003). Refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation by flecainide. Cardiovasc Drugs Ther 17: 237247.
  • Anno T, Hondeghem LM (1990). Interactions of flecainide with guinea-pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circ Res 66: 789803.
  • Antzelevitch C (2006). Brugada syndrome. Pacing Clin Electrophysiol 29: 11301159.
  • Antzelevitch C, Yan GX, Shimizu W (1999). Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J Electrocardiol 32 (Suppl.): 158165.
  • Bean BP, Cohen CJ, Tsien RW (1983). Lidocaine block of cardiac sodium channels. J Gen Physiol 81: 613642.
  • Bellemin-Baurreau J, Poizot A, Hicks PE, Armstrong JM (1994). An in vitro method for the evaluation of antiarrhythmic and antiischemic agents by using programmed electrical stimulation of rabbit heart. J Pharmacol Toxicol Methods 31: 3140.
  • Bezanilla F, Armstrong CM (1977). Inactivation of the sodium channel. I. Sodium current experiments. J Gen Physiol 70: 549566.
  • Brugada J, Boersma L, Kirchhof C, Allessie M (1991). Proarrhythmic effects of flecainide: experimental evidence for increased susceptibility to reentrant arrhythmias. Circulation 84: 18081818.
  • Carmeliet E, Mubagwa K (1998). Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol 70: 172.
  • Clements-Jewery H, Kanaganaygam GS, Kabra R, Curtis MJ (2006). Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. Br J Pharmacol 147: 468475.
  • Cubeddu LX (2003). QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 10: 452457.
  • Darpo B, Nebout T, Sager PT (2006). Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: the International Conference on Harmonization of Technical Requirement for Registration of Pharmaceuticals for Human Use E14 guidance. J Clin Pharmacol 46: 498507.
  • Dubin AE, Nasser N, Rohrbacher J, Hermans AN, Marrannes R, Grantham C et al. (2005). Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 10: 168181.
  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmias Suppression Trial. N Engl J Med 324: 781788.
  • Food and Drug Administration (2005). HRS: International Conference on Harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability. Fed Regist 70: 6113361134.
  • Gellens ME, George Al, Chen L, Chahine M, Horn R, Barchi RL et al. (1992). Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci USA 89: 554558.
  • Greenberg HM, Dwyer EMJ, Hochman JS, Steinberg JS, Echt DS, Peters RW (1995). Interaction of ischemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 74: 631635.
  • Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J et al. (2001). Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 88: 333339.
  • Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85100.
  • Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications: report on a Policy Conference on the European Society of Cardiology. Cardiovasc Res 47: 219233.
  • Kou WH, Nelson SD, Lynch JJ, Montgomery DG, DiCarlo L, Lucchesi BR (1987). Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 9: 359365.
  • Lathers CM, Schraeder PL (2002). Clinical pharmacology: drugs as a benefit and/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol 42: 123136.
  • Levine JH, Morganroth J, Kadish AH (1989). Mechanisms and risk factors for proarrhythmias with type Ia compared with Ic antiarrhythmic drug therapy. Circulation 80: 10631069.
  • Lu HR, Mariën R, Saels A, De Clerck F (2001). Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol 12: 93102.
  • Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R et al. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guidelines. Br J Pharmacol 154: 14271438.
  • Patterson E, Gibson JK, Lucchesi BR (1988). Antiarrhythmic and arrhythmogenic actions of methyl lidocaine during the recovery phase after canine myocardial infarction. Pharmacology 36: 7383.
  • Ragsdale DS, McPhee JC, Scheuer T, Catterall WA (1996). Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci USA 93: 92709275.
  • Ranger S, Nattel S (1995). Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation 92: 13001311.
  • Ranger S, Talajic M, Lemery R, Roy D, Nattel S (1989). Amplification flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade. Circulation 79: 10001006.
  • Roden DM (2008). Long-QT syndrome. N Engl J Med 358: 169176.
  • Sakai T, Ogawa S, Hosokawa M, Miyazaki T, Sakurai K, Nakamura Y (1989). Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. Cardiovas Res 23: 177183.
  • Sellers TD, DiMarco JP (1984). Sinusoidal ventricular tachycardia associated with flecainide acetate. Chest 85: 647649.
  • Shah RR (2004). Pharmacogenetic aspects of drug-induced torsade de pointes. Drug Saf 27: 145172.
  • The CAST Investigators (1989). Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406412.
  • Walczak T (2003). Do antiepileptic drugs play a role in sudden unexpected death in epilepsy? Drug Saf 26: 673683.
  • Wang D, Patel C, Cui C, Yan G-X (2008). Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Ther 119: 141151.
  • Wyman MG, Wyman RM, Cannom DS, Criley JM (2004). Prevention of primary fibrillation in acute myocardial infarction with prophylactic lidocaine. Am J Cardiol 94: 545551.
  • Yan GX, Antzelevitch C (1999). Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100: 16601666.
  • Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR (2001). Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103: 28512856.
  • Zehender M, Kasper W, Just H (1990). Lidocaine in the early phase of acute myocardial infarction: the controversy over prophylactic or selective use. Clin Cardiol 13: 534539.